Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on August 25, 2026

Annovis to Host Corporate Update Webinar on September 2, 2026
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
Ocugen to Participate in Upcoming September Investor and Industry Conferences
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
Immatics Announces $150 Million Underwritten Offering
Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
 Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
Revier Therapeutics startet mit 6 Mio. € Seed-Finanzierung zur Entwicklung von Klasse-IIa-HDAC-Inhibitoren für kardiometabolische Erkrankungen
Revier Therapeutics Launches with €6 Million Seed Financing to  Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease
Les Canadiens champions de la longévité... en mauvaise santé

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.